Methods for etiologic and early marker investigations in the PLCO trial

Richard B. Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen Yi Huang; Paul Pinsky; Douglas Reding; Edward P. Gelmann; Nat Rothman; Ruth M. Pfeiffer; Robert N. Hoover; Christine D. Berg

doi:10.1016/j.mrfmmm.2005.06.013

Methods for etiologic and early marker investigations in the PLCO trial

Richard B. Hayes, Alice Sigurdson, Lee Moore, Ulrike Peters, Wen Yi Huang, Paul Pinsky, Douglas Reding, Edward P. Gelmann, Nat Rothman, Ruth M. Pfeiffer, Robert N. Hoover, Christine D. Berg

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Abstract

With the rapid development of biomarkers and new technologies, large-scale biologically-based cohort studies present expanding opportunities for population-based research on disease etiology and early detection markers. The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial is a large randomized trial designed to determine if screening for these cancers leads to mortality reduction for these diseases. Within the Trial, the PLCO etiology and early marker study (EEMS) identifies risk factors for cancer and other diseases and evaluates biologic markers for the early detection of disease. EEMS includes 155,000 volunteers who provide basic risk factor information. Serial blood samples are collected at each of six screening rounds (including one collection for cryopreserved whole blood) from screening arm participants (77,000 subjects) and buccal cells are collected from those in the control arm of the trial. Etiologic studies consider environmental (e.g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial.

Original language	English (US)
Pages (from-to)	147-154
Number of pages	8
Journal	Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Volume	592
Issue number	1-2
DOIs	https://doi.org/10.1016/j.mrfmmm.2005.06.013
State	Published - Dec 30 2005
Externally published	Yes

Keywords

Cancer
Cohort
Molecular epidemiology

ASJC Scopus subject areas

Molecular Biology
Genetics
Health, Toxicology and Mutagenesis

Access to Document

10.1016/j.mrfmmm.2005.06.013

Cite this

Hayes, R. B., Sigurdson, A., Moore, L., Peters, U., Huang, W. Y., Pinsky, P., Reding, D., Gelmann, E. P., Rothman, N., Pfeiffer, R. M., Hoover, R. N., & Berg, C. D. (2005). Methods for etiologic and early marker investigations in the PLCO trial. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 592(1-2), 147-154. https://doi.org/10.1016/j.mrfmmm.2005.06.013

Hayes, RB, Sigurdson, A, Moore, L, Peters, U, Huang, WY, Pinsky, P, Reding, D, Gelmann, EP, Rothman, N, Pfeiffer, RM, Hoover, RN & Berg, CD 2005, 'Methods for etiologic and early marker investigations in the PLCO trial', Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 592, no. 1-2, pp. 147-154. https://doi.org/10.1016/j.mrfmmm.2005.06.013

@article{7600a93e7e284a72a0d821a929826d09,

title = "Methods for etiologic and early marker investigations in the PLCO trial",

abstract = "With the rapid development of biomarkers and new technologies, large-scale biologically-based cohort studies present expanding opportunities for population-based research on disease etiology and early detection markers. The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial is a large randomized trial designed to determine if screening for these cancers leads to mortality reduction for these diseases. Within the Trial, the PLCO etiology and early marker study (EEMS) identifies risk factors for cancer and other diseases and evaluates biologic markers for the early detection of disease. EEMS includes 155,000 volunteers who provide basic risk factor information. Serial blood samples are collected at each of six screening rounds (including one collection for cryopreserved whole blood) from screening arm participants (77,000 subjects) and buccal cells are collected from those in the control arm of the trial. Etiologic studies consider environmental (e.g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial.",

keywords = "Cancer, Cohort, Molecular epidemiology",

author = "Hayes, {Richard B.} and Alice Sigurdson and Lee Moore and Ulrike Peters and Huang, {Wen Yi} and Paul Pinsky and Douglas Reding and Gelmann, {Edward P.} and Nat Rothman and Pfeiffer, {Ruth M.} and Hoover, {Robert N.} and Berg, {Christine D.}",

year = "2005",

month = dec,

day = "30",

doi = "10.1016/j.mrfmmm.2005.06.013",

language = "English (US)",

volume = "592",

pages = "147--154",

journal = "Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis",

issn = "0027-5107",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Methods for etiologic and early marker investigations in the PLCO trial

AU - Hayes, Richard B.

AU - Sigurdson, Alice

AU - Moore, Lee

AU - Peters, Ulrike

AU - Huang, Wen Yi

AU - Pinsky, Paul

AU - Reding, Douglas

AU - Gelmann, Edward P.

AU - Rothman, Nat

AU - Pfeiffer, Ruth M.

AU - Hoover, Robert N.

AU - Berg, Christine D.

PY - 2005/12/30

Y1 - 2005/12/30

N2 - With the rapid development of biomarkers and new technologies, large-scale biologically-based cohort studies present expanding opportunities for population-based research on disease etiology and early detection markers. The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial is a large randomized trial designed to determine if screening for these cancers leads to mortality reduction for these diseases. Within the Trial, the PLCO etiology and early marker study (EEMS) identifies risk factors for cancer and other diseases and evaluates biologic markers for the early detection of disease. EEMS includes 155,000 volunteers who provide basic risk factor information. Serial blood samples are collected at each of six screening rounds (including one collection for cryopreserved whole blood) from screening arm participants (77,000 subjects) and buccal cells are collected from those in the control arm of the trial. Etiologic studies consider environmental (e.g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial.

AB - With the rapid development of biomarkers and new technologies, large-scale biologically-based cohort studies present expanding opportunities for population-based research on disease etiology and early detection markers. The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial is a large randomized trial designed to determine if screening for these cancers leads to mortality reduction for these diseases. Within the Trial, the PLCO etiology and early marker study (EEMS) identifies risk factors for cancer and other diseases and evaluates biologic markers for the early detection of disease. EEMS includes 155,000 volunteers who provide basic risk factor information. Serial blood samples are collected at each of six screening rounds (including one collection for cryopreserved whole blood) from screening arm participants (77,000 subjects) and buccal cells are collected from those in the control arm of the trial. Etiologic studies consider environmental (e.g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial.

KW - Cancer

KW - Cohort

KW - Molecular epidemiology

UR - http://www.scopus.com/inward/record.url?scp=28244472719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244472719&partnerID=8YFLogxK

U2 - 10.1016/j.mrfmmm.2005.06.013

DO - 10.1016/j.mrfmmm.2005.06.013

M3 - Article

C2 - 16054167

AN - SCOPUS:28244472719

SN - 0027-5107

VL - 592

SP - 147

EP - 154

JO - Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

JF - Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

IS - 1-2

ER -

Methods for etiologic and early marker investigations in the PLCO trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this